EE165 A Cost-Consequence Analysis of Ponatinib Versus Imatinib in Patients with Newly Diagnosed Philadelphia-Positive Acute Lymphoblastic Leukemia in the United States
Abstract
Authors
LG Hernandez S Davies C Li LE Reddick I Jensen